ADVI Experts Discuss the IRA and 2024 Election at Asembia’s AXS24 Summit
Lindsay Bealor Greenleaf, JD, MBA
May 7, 2024
On April 30, 2024, Sarah Butler, chief commercial officer of ADVI Health, Lindsay Bealor Greenleaf, solution leader for Federal and State Policy at ADVI Health, Hillary Cavanagh, senior director at PhRMA, and Lyn Fitzgerald, chief growth officer, at Ontada hosted a panel presentation at Asembia AXS24 on “Election Policy Issues and the Patient Journey Ripple Effect: IRA, The War on Cancer.”
In this panel discussion, they discussed the major healthcare issues impacting the 2024 Election, the big innovation and drug development issues tied to the drug pricing provisions of the Inflation Reduction Act, Part D Redesign, and their potential implications for patients, providers, and payers.
Hear more from Sarah and Lindsay as they sheds light on key insights from the panel discussion as well as takeaways from Asembia’s AXS24 Summit.
Learn More
ADVI experts will continue to analyze trends throughout the implementation of the Inflation Reduction Act (IRA) and the 2024 presidential election. Get in touch today to gain expert insights on the IRA and the evolving healthcare landscape.
Lindsay Bealor Greenleaf, JD, MBA
Senior Vice President, Market Access and Policy Strategy
CEO insights
Related articles
Real analysis from people who’ve been there
The 2026 Rare Disease Reality
Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …
Marc Samuels, JD, MPH
February 26, 2026
AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption
Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …
Marc Samuels, JD, MPH
December 30, 2025
2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption
In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …
Marc Samuels, JD, MPH
December 16, 2025
What HEOR Information Does CMS Need for Drug Price Negotiations Under the IRA?
As the Inflation Reduction Act (IRA) reshapes drug pricing policy in the United States, the Centers for Medicare and Medicaid (CMS) …
Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care
CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …
Alicia Silver, MPP
November 21, 2025
Real-World Effectiveness vs Clinical Trial Efficacy in Medicare
The Inflation Reduction Act (IRA) has ushered in a new era of drug pricing negotiations in the US. For the …
Why is Medicare Data Central to IRA Negotiations?
The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …
The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development
Rare diseases impact nearly 1 in 10 people in the US and are largely untreated, with 95 percent lacking FDA-approved …
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.